Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity
Corbus Pharmaceuticals reported positive topline data from the CANYON-1 Phase 1b trial of CRB-913 in obesity, with statistically significant weight loss at all three doses and a placebo-adjusted mean weight loss of 5.0% at 12 weeks for the 60 mg dose (p<0.0001 at every dose), with no plateau observed. Safety was the key differentiator: psychiatric adverse events were broadly in line with GLP-1 drugs, with no suicidality and only one transient depressive symptom among 188 dosed participants, and GI events were markedly lower than oral semaglutide and orforglipron in cross-trial comparisons.
Key figures
- Drug Name
- CRB-913
- Phase Of Trial
- Phase 1b
- Study sites
- 15
- Next milestone
- Phase 2 monotherapy study expected to initiate in H1 2027
- P value vs placebo
- <0.0001
- Treatment duration
- 12 weeks dosing plus 4 weeks follow-up
- Weight loss 20mg pct
- 2.8
- Weight loss 40mg pct
- 3.3
- Weight loss 60mg pct
- 5
- Participants enrolled
- 254
- Weight loss placebo pct
- 0
- Max weight loss 60mg pct
- 13.4
- Responder rate 5pct 60mg
- 44.4%
- Responder rate 7.5pct 60mg
- 6.7%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.